Consult combines trusted medical literature with real-world evidence showing how comparable patients are being treated and how care patterns are changing.
Ask a question
For patients with type 2 diabetes and coexisting heart failure and chronic kidney disease, an SGLT2 inhibitor is recommended as first-line therapy. This class lowers the risk of heart failure hospitalization and slows progression of chronic kidney disease, independent of its glucose-lowering effect.
For most patients with type 2 diabetes and heart failure, an SGLT2 inhibitor is the preferred choice because it has the strongest evidence for reducing heart failure hospitalizations and slowing progression of chronic kidney disease.
Top 5 national prescribing patterns associated with bacterial infections (Jun 2025–Feb 2026)
Grounded in content from sources clinicians trust
The relevant guideline and source detail for further review.
A direct synthesis of the medical literature addressing your question.
How comparable patients are being treated and how care patterns are changing.
Why Consult
Fast enough for the moment. Detailed enough to verify.
Trace every answer back to the supporting literature and guidelines.
Get a concise, structured answer in 30 to 60 seconds.
Move promising clinical questions into further investigation through Jiro Research.
Earn continuing medical education credit for eligible clinical questions.
Build points and earn Perks dollars as you learn and practice.
Consult is free for every verified clinician in the U.S. Sign up
with your NPI in under a minute. No EHR integration required.
NPI-only signup. No EHR integration required.